Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
www.pulmccm.org
Jones et al randomized 1,647 people with moderate to severe COPD for the two trials, to receive either aclidinium inhaled (a potential tiotropium competitor) once daily or placebo for 1 year. Aclidinium improved FEV1 by ~65 mL. An absolute ~8% more people taking the drug achieved a 4-point
Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
Phase III trials for aclidinium, a "me-too…
Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
Jones et al randomized 1,647 people with moderate to severe COPD for the two trials, to receive either aclidinium inhaled (a potential tiotropium competitor) once daily or placebo for 1 year. Aclidinium improved FEV1 by ~65 mL. An absolute ~8% more people taking the drug achieved a 4-point